JWH-210

JWH-210 is a synthetic cannabinoid in the naphthoylindole family. It contains an ethyl substituent at the 4-position of the naphthalene ring and has very high affinity for CB₁ and CB₂ receptors. JWH-210 was identified in herbal smoking products in Europe from 2010 and has been studied in receptor assays, animal models and forensic investigations.

Chemistry and history

JWH-210 is (4-ethyl-1-naphthalenyl)(1-pentyl-1H-indol-3-yl)methanone. It shares the naphthoylindole scaffold of JWH-018, but carries an ethyl group at the 4-position of the naphthalene ring. It was first reported to the European monitoring system in September 2010 and was detected in bulk powders, herbal smoking mixtures and herbal cannabis samples (EUDA: Synthetic cannabinoids in Europe).

Pharmacology

JWH-210 is a high-affinity agonist at CB₁ and CB₂ receptors. A commonly cited receptor study reported Ki values of approximately 0.46 nM at CB₁ and 0.69 nM at CB₂, placing it among the more potent compounds in the early JWH series (Comparative cannabinoid receptor affinity data).

A 2014 study comparing JWH-073, JWH-081 and JWH-210 found that JWH-210 had the highest CB₁ affinity of the three. In the same study, the animals did not show active responses in the self-administration procedure, a result limited to that particular model and experimental design (Dependence potential of JWH-073, JWH-081 and JWH-210, 2014).

Reported effects

There is limited human information that isolates JWH-210 from other synthetic cannabinoids in commercial products. Its high CB₁ affinity is consistent with cannabimimetic activity, but it does not establish a predictable subjective experience or a direct comparison with cannabis.

Clinical reports involving synthetic cannabinoid mixtures describe altered perception, anxiety, agitation, confusion, sedation and cardiovascular symptoms. Product composition and co-exposure often complicate the interpretation of individual cases.

Forensic and toxicological findings

JWH-210 has been detected in commercial herbal products and in forensic samples. A US forensic identification study found it in products alongside JWH-018, JWH-073, JWH-200 and JWH-250, sometimes with more than one active substance in the same material (Logan and colleagues, 2012).

A reliable relationship between JWH-210 concentrations and toxicity in humans has not been established in the available literature. Its receptor potency and detection in products establish biological activity and market presence, without precisely establishing the clinical risk.

Toxicity and research limitations

Human pharmacokinetic and metabolism data specific to JWH-210 remain limited. The animal self-administration study did not demonstrate reinforcement under its test conditions, but that single result should not be interpreted as proof that the compound has no abuse potential. More direct human and preclinical work would be needed to characterise its longer-term effects.

Related compounds

JWH-210 is related to JWH-018, JWH-073, JWH-122 and JWH-398. It is the 4-ethyl analogue of the naphthoylindole scaffold.